The NMDA Receptor Hypofunction Model of Psychosis

Annals of the New York Academy of Sciences

Volumn 1003, Issue , 2003, Pages 119-130

  Farber, Nuri B ^a,b  

^a WASHINGTON UNIVERSITY   (United States)

^b WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Bipolar disorder; Dissociative anesthetics; Dizocilpine maleate; Ketamine; NMDA antagonists; Phencyclidine; Psychoses; Psychosis; Schizophrenia

Indexed keywords

4 AMINOBUTYRIC ACID; 4 PHOSPHONOMETHYLPIPECOLIC ACID; ACETYLCHOLINE; ALPHA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BRAIN DERIVED NEUROTROPHIC FACTOR; CLOZAPINE; DOPAMINE; GLUTAMATE RECEPTOR; GLUTAMATE RECEPTOR ANTAGONIST; GLUTAMIC ACID; HALOTHANE; HEAT SHOCK PROTEIN; HEAT SHOCK PROTEIN 70; KETAMINE; LAMOTRIGINE; LIGAND; LORAZEPAM; MUSCARINIC RECEPTOR; MUSCARINIC RECEPTOR BLOCKING AGENT; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; NEUROTRANSMITTER; NORADRENALIN; PHENCYCLIDINE; PROTEIN C FOS; PROTEIN C JUN; PSYCHEDELIC AGENT; SEROTONIN; SEROTONIN RECEPTOR; UNINDEXED DRUG;

BEHAVIOR; BRAIN FUNCTION; BRAIN METABOLISM; CHOLINERGIC SYSTEM; CLINICAL FEATURE; COGNITION; CONCENTRATION RESPONSE; CONFERENCE PAPER; DISEASE EXACERBATION; DRUG ACTIVITY; DRUG EFFECT; EXCITATION; FOREBRAIN; GABAERGIC SYSTEM; HISTOPATHOLOGY; HUMAN; HYPERMETABOLISM; HYPOTHESIS; IDIOPATHIC DISEASE; IMMEDIATE EARLY GENE; INTERNEURON; MEMORY; MEMORY DISORDER; MENTAL DISEASE; MODEL; NEUROCHEMISTRY; NEUROPATHOLOGY; NEUROTOXICITY; NEUROTRANSMISSION; NEUROTRANSMITTER RELEASE; NONHUMAN; NORADRENERGIC SYSTEM; ONSET AGE; PATHOPHYSIOLOGY; PROTEIN FUNCTION; PSYCHOSIS; RODENT; SCHIZOPHRENIA; SYNDROME; THALAMUS;

RODENTIA;

EID: 0345830623     PISSN: 00778923     EISSN: None     Source Type: Book Series    
DOI: 10.1196/annals.1300.008     Document Type: Conference Paper

References (62)

1. WHITE, P.F., W.L. WAY & A.J. TREVOR. 1982. Ketamine - its pharmacology and therapeutic uses. Anesthesiology 56: 119-136.
2. REICH, D.L. & G. SILVAY. 1989. Ketamine: an update on the first twenty-five years of clinical experience. Can. J. Anaesth. 36: 186-197.
3. KRYSTAL, J.H., L.P. KARPER, J.P. SEIBYL, et al. 1994. Subanesthetic effects of the non-competitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses. Arch. Gen. Psychiatry 51: 199-214.
4. MALHOTRA, A.K., D.A. PINALS, H. WEINGARTNER, et al. 1996. NMDA receptor function and human cognition: the effects of ketamine in healthy volunteers. Neuropsychopharmacology 14: 301-307.
5. NEWCOMER, J.W., N.B. FARBER, V. JEVTOVIC-TODOROVIC, et al. 1999. Ketamine-induced NMDA receptor hypofunction as a model of memory impairment in schizophrenia. Neuropsychopharmacology 20: 106-118.
6. MOGHADDAM, B. & B. ADAMS. 1998. Reversal of phencyclidine effects by a group 11 metabotropic glutamate receptor agonist in rats. Science 281: 1349-1352.
7. MOGHADDAM, B., B. ADAMS, A. VERMA, et al. 1997. Activation of glutamatergic neurotransmission by ketamine: a novel step in the pathway from NMDA receptor blockade to dopaminergic and cognitive disruptions associated with the prefrontal cortex. J. Neurosci. 17: 2921-2927.
8. NOGUCHI, K., R. JOHNSON & G. ELLISON. 1998. The effects of MK-801 on aspartate and glutamate levels in the anterior cingulate and retrosplenial cortices: an in vivo microdialysis study. Soc. Neurosci. Abstr. 24: 233.
9. HASEGAWA, M., H. KINOSHITA, M. AMANO, et al. 1993. MK-801 increases endogenous acetylcholine release in the rat parietal cortex: a study using brain microdialysis. Neurosci. Lett. 150: 53-56.
10. GIOVANNINI, M.G., D. MUTOLO, L. BIANCHI, et al. 1994. NMDA receptor antagonists decrease GABA outflow from the septum and increase acetylcholine outflow from the hippocampus: a microdialysis study. J. Neurosci. 14: 1358-1365.
11. 2-adrenergic agonists. Mol. Psychiatry 4: 344-352.
12. OLNEY, J.W. & N.B. FARBER. 1995. Glutamate receptor dysfunction and schizophrenia. Arch. Gen. Psychiatry 52: 998-1007.
13. OLNEY, J.W., J. LABRUYERE & M.T. PRICE. 1989. Pathological changes induced in cerebrocortical neurons by phencyclidine and related drugs. Science 244: 1360-1362.
14. ELLISON, G. 1994. Competitive and non-competitive NMDA antagonists induce similar limbic degeneration. Neuroreport 5: 2688-2692.
15. CORSO, T.D., M.A. SESMA, T.I. TENKOVA, et al. 1997. Multifocal brain damage induced by phencyclidine is augmented by pilocarpine. Brain Res. 752: 1-14.
16. HORVATH, Z.C., J. CZOPF & G. BUZSAKI. 1997. MK-801-induced neuronal damage in rats. Brain Res. 753: 181-195.
17. FARBER, N.B., S.H. KIM, K. DIKRANIAN, et al. 2002. Receptor mechanisms and circuitry underlying NMDA antagonist neurotoxicity. Mol. Psychiatry 7: 32-43.
18. FARBER, N.B., X.P. JIANG, K. DIKRANIAN, et al. Muscimol prevents NMDA antagonist neurotoxicity by activating GABAA receptors in several brain regions. Brain Res. In press.
19. 2 Adrenergic agonists prevent MK-801 neurotoxicity. Neuropsychopharmacology 12: 347-349.
20. 2A receptors prevent NMDA antagonist neurotoxicity. Neuropsychopharmacology 18: 57-62.
21. GRUNZE, H.C., D.G. RAINNIE, M.E. HASSELMO, et al. 1996. NMDA-dependent modulation of CA1 local circuit inhibition. J. Neurosci. 16: 2034-2043.
22. MEIBACH, R.C., D. GLICKS, R. Cox, et al. 1979. Localisation of phencyclidine-induced changes in brain energy metabolism. Nature 282: 625-626.
23. NELSOM, S.R., R.B. HOWARD, R.S. CROSS, et al. 1980. Ketamine-induced changes in regional glucose utilization in the rat brain. Anesthesiology 52: 330-334.
24. KURUMAJI, A. & J. MCCULLOCH. 1989. Effects of MK-801 upon local cerebral glucose utilisation in conscious rats and in rats anaesthetised with halothane. J. Cereb. Blood Flow Metab. 9: 786-794.
25. DUNCAN, G.E., S.S. MOY, D.J. KNAPP, et al. 1998. Metabolic mapping of the rat brain after subanesthetic doses of ketamine: potential relevance to schizophrenia. Brain Res. 787: 181-190.
26. DUNCAN, G.E., J.N. LEIPZIG, R.B. MAILMAN, et al. 1998. Differential effects of clozapine and haloperidol on ketamine-induced brain metabolic activation. Brain Res. 812: 65-75.
27. ISHIMARU, M., F. FUKAMAUCHI & J.W. OLNEY. 1995. Halothane prevents MK-801 neurotoxicity in the rat cingulate cortex. Neurosci. Lett. 193: 1-4.
28. FARBER, N.B., M.T. PRICE, J. LABRUYERE, et al. 1993. Antipsychotic drugs block phencyclidine receptor-mediated neurotoxicity. Biol. Psychiatry 34: 119-121.
29. DRAGUNOW, M. & R.L.M. FAULL. 1990. MK-801 induces c-fos protein in thalamic and neocortical neurons of rat brain. Neurosci. Lett. 111: 39-45.
30. GASS, P., T. HERDEGEN, R. BRAVO, et al. 1993. Induction and suppression of immediate early genes in specific rat brain regions by the non-competitive N-methyl-D-aspartate antagonist, MK-801. Neuroscience 53: 749-758.
31. HUGHES, P., M. DRAGUNOW, E. BEILHARZ, et al. 1993. MK801 induces immediate-early gene proteins and BDNF mRNA in rat cerebrocortical neurones. NeuroReport 4: 183-186.
32. NAKAO, S.I., T. ADACHI, M. MURAKAWA, et al. 1996. Halothane and diazepam inhibit ketamine-induced c-fos expression in the rat cingulate cortex. Anesthesiology 85: 874-882.
33. NAKKI, R., F.R. SHARP, S.M. SAGAR, et al. 1996. Effects of phencyclidine on immediate early gene expression in the brain. J. Neurosci. Res. 45: 13-27.
34. GAO, X.M., T. HASHIMOTO & C.A. TAMMINGA. 1998. Phencyclidine (PCP) and dizocilpine (MK801) exert time-dependent effects on the expression of immediate early genes in rat brain. Synapse 29: 14-28.
35. OLNEY, J.W., J. LABRUYERE, G. WANG, et al. 1991. NMDA antagonist neurotoxicity: mechanism and prevention. Science 254: 1515-1518.
36. SHARP, F.R., P. JASPER, J. HALL, et al. 1991. MK-801 and ketamine induce heat shock protein HSP72 in injured neurons in posterior cingulate and retrosplenial cortex. Ann. Neurology 30: 801-809.
37. CASTREN, E., M. DA PHENA BERZAGHI, D. LINDHOLM, et al. 1993. Differential effects of MK-801 on brain-derived neurotrophic factor mRNA levels in different regions of the rat brain. Exp. Neurology 122: 244-252.
38. FARBER, N.B., D.F. WOZNIAK, M.T. PRICE, et al. 1995. Age specific neurotoxicity in the rat associated with NMDA receptor blockade: potential relevance to schizophrenia? Biol. Psychiatry 38: 788-796.
39. SHARP, F.R., M. BUTMAN, S. WANG, et al. 1992. Haloperidol prevents induction of the hsp70 heat shock gene in neurons injured by phencyclidine (PCP), MK801, and ketamine. J. Neurosci. Res. 33: 605-616.
40. SATO, D., A. UMINO, K. KANEDA, et al. 1997. Developmental changes in distribution patterns of phencyclidine-induced c-Fos in rat forebrain. Neurosci. Lett. 239: 21-24.
41. KRYSTAL, J.H., L.P. KARPER, A. BENNETT, et al. 1998. Interactive effects of subanesthetic ketamine and subhypnotic lorazepam in humans. Psychopharmacology 135: 213-229.
42. NEWCOMER, J.W., N.B. FARBER, G. SELKE, et al. 1998. Guanabenz effects on NMDA antagonist-induced mental symptoms in humans. Soc. Neurosci. Abstr. 24: 525.
43. LEVANEN, J., M.L. MAKELA & H. SCHEININ. 1995. Dexmedetomidine premedication attenuates ketamine-induced cardiostimulatory effects and postanesthetic delirium. Anesthesiology 82: 1117-1125.
44. HANDA, F., M. TANAKA, T. NISHIKAWA, et al. 2000. Effects of oral clonidine premedication on side effects of intravenous ketamine anesthesia: a randomized, double-blind, placebo-controlled study. J. Clin. Anaesth. 12: 19-24.
45. FARBER, N.B., X.P. JIANG, C. HEINKEL, et al. 2002. Antiepileptic drugs and agents that inhibit voltage-gated sodium channels prevent NMDA antagonist neurotoxicity. Mol. Psychiatry 7: 726-733.
46. ANAND, A., D.S. CHARNEY, D.A. OREN, et al. 2000. Attenuation of the neuropsychiatric effects of ketamine with lamotrigine. Arch. Gen. Psychiatry 57: 270-276.
47. MALHOTRA, A.K., C.M. ADLER, S.D. KENNISON, et al. 1997. Clozapine blunts N-methyl-D-aspartate antagonist-induced psychosis: a study with ketamine. Biol. Psychiatry 42: 664-668.
48. KRYSTAL, J.H., D.C. D'SOUZA, L.P. KARPER, et al. 1999. Interactive effects of subanesthetic ketamine and haloperidol in healthy humans. Psychopharmacology 145: 193-204.
49. ADAMS, B. & B. MOGHADDAM. 1998. Corticolimbic dopamine neurotransmission is temporally dissociated from the cognitive and locomotor effects of phencyclidine. J. Neurosci. 18: 5545-5554.
50. STRAUB, R.E., Y. JIANG, C.J. MACLEAN, et al. 2002. Genetic variation in the 6p22.3 gene DTNBP1, the human ortholog of the mouse dysbindin gene, is associated with schizophrenia. Am. J. Hum. Genet. 71: 337-48.
51. CHUMAKOV, I., M. BLUMENFELD, O. GUERASSIMENKO, et al. 2002. Genetic and physiological data implicating the new human gene G72 and the gene for D-amino acid oxidase in schizophrenia. Proc. Natl. Acad. Sci. USA 99: 13675-13680.
52. STEFANSSON, H., E. SIGURDSSON, V. STEINTHORSDOTTIR, et al. 2002. Neuregulin 1 and susceptibility to schizophrenia. Am. J. Hum. Genet. 71: 877-892.
53. IKONOMIDOU, C., P. BITTIGAU, M.J. ISHIMARU, et al. 2000. Ethanol-induced apoptotic neurodegeneration and fetal alcohol syndrome. Science 287: 1056-1060.
54. FAMY, C., A.P. STREISSGUTH & A.S. UNIS. 1998. Mental illness in adults with fetal alcohol syndrome or fetal alcohol effects. Am. J. Psychiatry 155: 552-554.
55. LOHR, J.B. & H.S. BRACHA. 1989. Can schizophrenia be related to prenatal exposure to alcohol? Some speculations. Schizophr. Bull. 15: 595-603.
56. BENES, F.M., J. MCSPARREN, E.D. BIRD, et al. 1991. Deficits in small interneurons in prefrontal and cingulate cortices of schizophrenic and schizoaffective patients. Arch. Gen. Psychiatry 48: 996-1001.
57. WOO, T.U., R.E. WHITEHEAD, D.S. MELCHITZKY, et al. 1998. A subclass of prefrontal gamma-aminobutyric acid axon terminals are selectively altered in schizophrenia. Proc. Natl. Acad. Sci. USA 95: 5341-5346.
58. 67) expression in schizophrenia and bipolar disorder. Arch. Gen. Psychiatry 57: 1061-1069.
59. TOMITAKA, S.I., K. HASHIMOTO, N. NARITA, et al. 1997. Regionally different effects of scopolamine on NMDA antagonist-induced heat shock protein HSP70. Brain Res. 736: 255-258.
60. SHARP, F.R., M. BUTMAN, J. KOISTINAHO, et al. 1994. Phencyclidine induction of the hsp70 stress gene in injured pyramidal neurons is mediated via multiple receptors and voltage gated calcium channels. Neuroscience 62: 1079-1092.
61. SHARP, J.W., D.L. PETERSEN & M.T. LANGFORD. 1995. DNQX inhibits phencyclidine (PCP) and ketamine induction of the hsp70 heat shock gene in the rat cingulate and retrosplenial cortex. Brain Res. 687: 114-124.
62. NAGATA, A., S. NAKAO, E. MIYAMOTO, et al. 1998. Propofol inhibits ketamine-induced c-fos expression in the rat posterior cingulate cortex. Anesth. Analg. 87: 1416-1420.